相关实验视频
Updated: Jul 24, 2025
04:16
Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
12.9K
埃斯莫洛尔对重症患者临床结果的影响:来自MIMIC-IV数据库的数据
Qihong Liang1,2, Lulan Li1,3, Kerong Chen1
1Department of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
概括
埃斯莫洛尔在重症患者的使用没有影响28天或90天的死亡率. 然而,埃斯莫洛尔治疗与血管压缩剂的使用和液体平衡的增加有关,以及心率降低,透静血压和平均动脉压力.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 心血管生理学心血管生理学
背景情况:
- 埃斯莫洛尔 (Esmolol) 是一种短效β-阻断剂,通常用于心室节律控制.
- 危急病患者经常经历血液动力学不稳定,需要像esmolol这样的干预措施.
- 埃斯莫洛尔对这一群体的死亡率的影响仍然是研究领域.
研究的目的:
- 评估埃斯莫洛尔 (esmolol) 给药与严重病情严重的成年患者的死亡率之间的关联.
- 评估二次结果,包括血管压缩剂的使用,血液动力学参数和液体平衡.
- 确定埃斯莫洛尔在重症监护室 (ICU) 设置中的潜在风险和益处.
主要方法:
- 使用MIMIC-IV数据库进行回顾性队列研究.
- 纳入标准:成年ICU患者的心率>100次/分钟.
- 统计分析包括多变量考克斯比例危险模型,后勤回归和倾向得分匹配 (PSM).
主要成果:
- 在PSM之前和之后,在esmolol和非esmolol组之间没有观察到28天或90天死亡率的显著差异.
- 埃斯莫洛尔治疗与血管压缩剂使用的显著增加有关 (HR 2.66,P < 0.001后PSM).
- 埃斯莫洛尔显著降低了心率,透气血压和平均动脉压,但并没有降低缩血压. 它还增加了24小时的液体平衡.
结论:
- 埃斯莫洛尔有效地降低了心率,并降低了急性病患者的舒张和平均动脉压.
- 观察到的血液动力学效应可能需要增加血管压缩器的支持,并导致液体过载.
- 尽管有血液动力学变化,但埃斯莫洛尔治疗与该队列28天或90天死亡率的增加无关.
相关概念视频
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
28
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
28
01:28Acute Coronary Syndrome IV: Interprofessional Care
12
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12
01:22Heart Failure Drugs: β-Blockers
368
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
368
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:30Acute Coronary Syndrome III: Diagnostic Studies
10
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
10
01:26Heart Failure Drugs: Inotropic Agents
635
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
635